Skip to content
You are now leaving https://www.ionispharma.com to visit

Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA® (volanesorsen) in Patients with Familial Partial Lipodystrophy

Study meets primary and key secondary endpoints BOSTON, Mass. and CARLSBAD, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today topline results from the